Skip to Main Content
Skip Nav Destination

The MYC Inhibitor, OMO-103, Demonstrates Safety and Preliminary Activity

February 15, 2024

Major Finding: OMO-103 shows safety as well as preliminary signs of drug activity in advanced solid tumors.

Concept: Target engagement and soluble immune-related potential response and predictive markers were demonstrated.

Impact: This first-in-modality trial indicates that further investigation into specific indications for OMO-103 is needed.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal